Watching
TXG · 10x Genomics, Inc.
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 9 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A daily close below $66.17, the 50-day moving average reported on 6 October 2026. A company-disclosed deferral of part of the roughly 40-unit 2026 Atera plan into 2027, or a full-year guidance cut below $610 million, also breaks the case.
Last pick Medium conviction, to : −14.3% against the S&P 500's +1.7%. Trailed the S&P 500 · conviction cut below medium.
Catalyst (in 23 days)
How picks are graded →The thesis
The shares of 10x Genomics now trade well ahead of a business that has just begun shipping its Atera spatial instrument. The odds of the shares beating the market before the third-quarter report have weakened. That report, expected around 4 November 2026, settles the case with the first Atera shipment count and a test of the $610–630 million revenue guidance.
The shares fell 17.5% on 6 October 2026 to close at $80.66, one session after a 52-week closing high of $97.74, per adjusted daily closes and GuruFocus. Neither GuruFocus nor MarketBeat cited any company news, filing or analyst action for the drop. The company's last operating news remains the 29 September 2026 announcement of first commercial Atera shipments.
Demand is the stronger part of the case. Output and timing are the weak parts. Management said on the 6 August 2026 second-quarter call that booked Atera orders greatly exceeded the roughly 40 units planned for 2026 and that manufacturing capacity limits shipments. The narrative is maturing: the Atera story is widely covered after five target changes and initiations in September, and the 6 October 2026 reversal came on no new information.
Bullish and bearish views on 10x Genomics, Inc.
The bull case on 10x Genomics, Inc. (TXG), in brief: Orders exceed the 2026 plan. The bear case: Underlying growth is still low.
Bull case
- Orders exceed the 2026 plan. The company said on 29 September 2026, when it began commercial Atera shipments, that booked orders exceeded the roughly 40 instruments it expects to ship in 2026. Management made the same point on the 6 August 2026 call.
- Guidance went up before launch. On 6 August 2026 the company raised full-year 2026 revenue guidance to $610–630 million from $600–625 million, per its second-quarter release (Form 8-K, Exhibit 99.1).
- Margins and cash fund the ramp. Second-quarter 2026 gross margin was 74%, and cash plus marketable securities totalled $552.0 million at 30 June 2026, per the same filing.
- Software and partners widen the platform. On 29 September 2026 the company launched Sentira, NVIDIA-accelerated spatial analysis software that it says cuts processing from hours to minutes. On 10 September 2026 it said it will add Lunit's AI pathology platform to its oncology workflow. The company has disclosed no revenue from either.
- The rate backdrop eased. Benzinga reported on 2 October 2026 that September payrolls rose 29,000 against 90,000 expected, which cut bets on a Federal Reserve rate hike. Rate-sensitive tools shares rallied that day.
Bear case
- Underlying growth is still low. Second-quarter 2026 revenue was $151.0 million, up 3% year over year excluding patent-settlement income. Instruments contributed $7.7 million, per the 6 August 2026 release.
- The third quarter is guided lower. Management said on 6 August 2026 that third-quarter revenue would step down modestly from the second quarter, with Atera shipments weighted to the fourth quarter. By design, the November report will carry little Atera revenue.
- The price sits far above the consensus. MarketBeat put the average analyst target at $53.93 on 6 October 2026, with 6 Buy, 11 Hold and 1 Sell ratings. Only Argus, which started coverage at Buy with a $110 target on 28 September 2026, sits above the $80.66 close. Leerink ($90), Piper Sandler ($80), RBC ($70) and UBS ($68) are at or below it.
- Insiders sold into the rally. MarketBeat counted about $11.8 million of insider sales in the 90 days to 6 October 2026, including 46,388 shares sold by Chief Financial Officer Adam Taich. A Form 4 shows Chief Executive Serge Saxonov sold 25,000 shares on 22 September 2026 at an average of $81.22.
- Sharp, unexplained reversals. The 17.5% one-day fall on 6 October 2026 came with no company news cited by GuruFocus or MarketBeat. That points to positioning, rather than fundamentals, setting the price for now.
Price setup
The shares closed at $80.66 on 6 October 2026, 17.5% below the $97.74 52-week closing high set on 5 October 2026, per adjusted daily closes. They are still up 87.1% over three months. The 14-day relative strength index (RSI), a momentum gauge running from 0 to 100, stood at 57.1, which is neither overbought nor oversold.
MarketBeat put the 50-day moving average at $66.17 and the 200-day moving average at $42.13 on 6 October 2026. The close sits about 22% above the 50-day average. That gap is wide, and the 50-day average is the first level a further pullback would test.
The September rally ran through about $81, the level of the chief executive's 22 September 2026 sale. A close back above $97.74 would show buyers absorbing the reversal. Closes under $66.17 would show the run since the Atera launch giving way.
Catalysts, next 30 days
- ~14 October 2026 (est.) — Company announcement of the third-quarter report date. The second-quarter date was announced on 15 July 2026, about three weeks before the report.
- 26 October 2026 — Short-interest data for the 15 October 2026 settlement date. A second positioning reading before the report.
- 28 October 2026 — Federal Reserve rate decision. Rate-hike expectations moved tools shares on 2 October 2026.
- ~4 November 2026 (est.) — Third-quarter 2026 results after the close. The company reported third-quarter 2025 results on 6 November 2025. This report gives the first Atera shipment count, a capacity update and a check on the $610–630 million guidance.
Elapsed catalysts
- 9 October 2026 — Short-interest data for the 30 September 2026 settlement date. Shows whether bearish positioning grew as the shares reached their high. (passed 3d ago)
What would change the view
The operating case breaks if the company pushes part of the roughly 40-unit 2026 Atera plan into 2027, or cuts full-year guidance below $610 million. Either result would mean the price got ahead of the business with no recovery in sight this year.
On price, a daily close below $66.17, the 50-day moving average reported on 6 October 2026, would show the post-launch rally failing. A shipment count on track for about 40 units, guidance held or raised, and a fresh close above the $97.74 high would make the case stronger than it reads today.
What it trades with
The shares trade with genomics and life-science tools names such as Illumina, Pacific Biosciences and Twist Bioscience, and they react to interest-rate expectations, as on 2 October 2026. The medtech and diagnostics group has drawn rising attention since late September. A broad pullback across those peers would weigh on the shares whatever Atera does. Strength across the group would not offset a missed shipment plan.
Notes
- Second-quarter 2025 revenue included patent-settlement income, so 2026 year-over-year comparisons are better read on the ex-settlement figures the company reports.
- An August 2026 jury verdict against Qiagen's Parse Biosciences awarded 10x Genomics $4.8 million; a permanent US injunction was sought but had not been granted as of 2 October 2026.
- The company had not announced its third-quarter 2026 report date as of 7 October 2026; past date announcements came about three weeks before each report.
Related · shared themes
ADPT
Adaptive Biotechnologies Corporation
Adaptive Biotechnologies' clonoSEQ test won NCCN and International Myeloma Society backing in September 2026, yet the shares slid to $26.09 by 8 October 2026; the Q3 report, expected around 4 November 2026, shows whether test volume confirms the re-rating.
AZTA
Azenta, Inc.
Azenta's recovery case rests on its 9% June-quarter organic growth repeating and on an $11 million cost-cut plan announced in October; the fiscal fourth-quarter report, expected around 20 November 2026, shows whether revenue and free cash flow confirm it.
CAI
Caris Life Sciences, Inc.
Caris Life Sciences is growing revenue faster than its 27–28% FY2026 guidance implies, though a steep fourth-quarter 2025 comparison narrows the room for a raise; the third-quarter report expected around 4 November 2026 shows whether guidance rises above $1.040 billion.
CDNA
CareDx, Inc.
CareDx's shares have more than doubled in three months on a raised 2026 revenue guide and a higher preliminary Medicare rate for AlloSure; the third-quarter report, expected around 3 November 2026, tests whether revenue stays on track for the $490–500 million guide.
See also · stocks to watch